

# Patrik Medstrand

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/9220939/publications.pdf>

Version: 2024-02-01

63  
papers

1,311  
citations

448610

19  
h-index

445137

33  
g-index

64  
all docs

64  
docs citations

64  
times ranked

1880  
citing authors

#	ARTICLE	IF	CITATIONS
1	Molecular Epidemiology and Transmission Dynamics of the HIV-1 Epidemic in Ethiopia: Epidemic Decline Coincided With Behavioral Interventions Before ART Scale-Up. <i>Frontiers in Microbiology</i> , 2022, 13, 821006.	1.5	1
2	Airborne Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) in Hospitals: Effects of Aerosol-Generating Procedures, HEPA-Filtration Units, Patient Viral Load, and Physical Distance. <i>Clinical Infectious Diseases</i> , 2022, 75, e89-e96.	2.9	24
3	Detection of SARS-CoV-2 RNA on surfaces in a COVID-19 hospital ward indicates airborne viral spread. <i>Journal of Hospital Infection</i> , 2022, 124, 121-122.	1.4	2
4	Pre-Treatment Integrase Inhibitor Resistance and Natural Polymorphisms among HIV-1 Subtype C Infected Patients in Ethiopia. <i>Viruses</i> , 2022, 14, 729.	1.5	8
5	SARS-CoV-2 in Exhaled Aerosol Particles from COVID-19 Cases and Its Association to Household Transmission. <i>Clinical Infectious Diseases</i> , 2022, 75, e50-e56.	2.9	20
6	All-Cause Mortality and Serious Non-AIDS Events in Adults With Low-level Human Immunodeficiency Virus Viremia During Combination Antiretroviral Therapy: Results From a Swedish Nationwide Observational Study. <i>Clinical Infectious Diseases</i> , 2021, 72, 2079-2086.	2.9	46
7	Drug Resistance in HIV-Positive Adults During the Initial Year of Antiretroviral Treatment at Ethiopian Health Centers. <i>Open Forum Infectious Diseases</i> , 2021, 8, ofab106.	0.4	1
8	Associations Between Plasma Human Immunodeficiency Virus (HIV) Ribonucleic Acid Levels and Incidence of Invasive Cancer in People With HIV After Initiation of Combination Antiretroviral Therapy. <i>Open Forum Infectious Diseases</i> , 2021, 8, ofab131.	0.4	2
9	Inverted CD8 T-Cell Exhaustion and Co-Stimulation Marker Balance Differentiate Aviremic HIV-2-Infected From Seronegative Individuals. <i>Frontiers in Immunology</i> , 2021, 12, 744530.	2.2	5
10	High level of HIV drug resistance and virological non-suppression among female sex workers in Ethiopia. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2021, Publish Ahead of Print, .	0.9	2
11	Interferon- $\beta$ -Inducible Protein 10 (IP-10) Kinetics after Antiretroviral Treatment Initiation in Ethiopian Adults with HIV. <i>Microbiology Spectrum</i> , 2021, 9, e0181021.	1.2	2
12	Sources of Airborne Norovirus in Hospital Outbreaks. <i>Clinical Infectious Diseases</i> , 2020, 70, 2023-2028.	2.9	54
13	Aerosolization and recovery of viable murine norovirus in an experimental setup. <i>Scientific Reports</i> , 2020, 10, 15941.	1.6	9
14	Exhaled respiratory particles during singing and talking. <i>Aerosol Science and Technology</i> , 2020, 54, 1245-1248.	1.5	170
15	The HIV care continuum and HIV-1 drug resistance among female sex workers: a key population in Guinea-Bissau. <i>AIDS Research and Therapy</i> , 2020, 17, 33.	0.7	8
16	HIV treatment in Guinea-Bissau: room for improvement and time for new treatment options. <i>AIDS Research and Therapy</i> , 2020, 17, 3.	0.7	4
17	Brief Report: Interferon- $\beta$ -Inducible Protein 10—A Potential Marker for Targeted Viral Load Monitoring of Antiretroviral Treatment?. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2020, 83, 475-478.	0.9	3
18	Socio-economic condition and lack of virological suppression among adults and adolescents receiving antiretroviral therapy in Ethiopia. <i>PLoS ONE</i> , 2020, 15, e0244066.	1.1	7

#	ARTICLE	IF	CITATIONS
19	Title is missing!. , 2020, 15, e0244066.		0
20	Title is missing!. , 2020, 15, e0244066.		0
21	Title is missing!. , 2020, 15, e0244066.		0
22	Title is missing!. , 2020, 15, e0244066.		0
23	Title is missing!. , 2020, 15, e0244066.		0
24	Title is missing!. , 2020, 15, e0244066.		0
25	A17â€fThe effect of intra-host evolution of HIV-2 capsid on disease progression. Virus Evolution, 2019, 5, .	2.2	0
26	HIV-2 as a model to identify a functional HIV cure. AIDS Research and Therapy, 2019, 16, 24.	0.7	24
27	New insights are game-changers in HIV-2 disease management â€ Authors' reply. Lancet HIV,the, 2019, 6, e214-e215.	2.1	4
28	Hydrogen peroxide vapour treatment inactivates norovirus but has limited effect on post-treatment viral RNA levels. Infectious Diseases, 2019, 51, 197-205.	1.4	10
29	Is lowâ€level <scp>HIV</scp>â€1 viraemia associated with elevated levels of markers of immune activation, coagulation and cardiovascular disease?. HIV Medicine, 2019, 20, 571-580.	1.0	19
30	Transmission dynamics study of tuberculosis isolates with whole genome sequencing in southern Sweden. Scientific Reports, 2019, 9, 4931.	1.6	21
31	Long-term follow-up of HIV-2-related AIDS and mortality in Guinea-Bissau: a prospective open cohort study. Lancet HIV,the, 2019, 6, e25-e31.	2.1	57
32	Low Postseroconversion CD4 + T-cell Level Is Associated with Faster Disease Progression and Higher Viral Evolutionary Rate in HIV-2 Infection. MBio, 2019, 10, .	1.8	7
33	Quantification of HIV-2 DNA in Whole Blood. Bio-protocol, 2019, 9, e3404.	0.2	1
34	Protease Inhibitors or NNRTIs as First-Line HIV-1 Treatment in West Africa (PIONA): A Randomized Controlled Trial. Journal of Acquired Immune Deficiency Syndromes (1999), 2018, 79, 386-393.	0.9	11
35	Prevalence of HIV-1 pretreatment drug resistance among treatment naÃve pregnant women in Bissau, Guinea Bissau. PLoS ONE, 2018, 13, e0206406.	1.1	11
36	HIV-genetic diversity and drug resistance transmission clusters in Gondar, Northern Ethiopia, 2003-2013. PLoS ONE, 2018, 13, e0205446.	1.1	22

#	ARTICLE	IF	CITATIONS
37	Molecular epidemiology of HIV-1 in Iceland: Early introductions, transmission dynamics and recent outbreaks among injection drug users. <i>Infection, Genetics and Evolution</i> , 2017, 49, 157-163.	1.0	19
38	Development of an algorithm for determination of the likelihood of virological failure in HIV-positive adults receiving antiretroviral therapy in decentralized care. <i>Global Health Action</i> , 2017, 10, 1371961.	0.7	3
39	Genetic characterization of human immunodeficiency virus type 1 transmission in the Middle East and North Africa. <i>Heliyon</i> , 2017, 3, e00352.	1.4	11
40	Decreasing prevalence of transmitted drug resistance among ART-naïve HIV-1-infected patients in Iceland, 1996–2012. <i>Infection Ecology and Epidemiology</i> , 2017, 7, 1328964.	0.5	6
41	Long-term Outcome of Antiretroviral Treatment in Patients With and Without Concomitant Tuberculosis Receiving Health Center–Based Care—Results From a Prospective Cohort Study. <i>Open Forum Infectious Diseases</i> , 2017, 4, ofx219.	0.4	13
42	Virological failure and all-cause mortality in HIV-positive adults with low-level viremia during antiretroviral treatment. <i>PLoS ONE</i> , 2017, 12, e0180761.	1.1	52
43	Hydrogen Peroxide Vapor Decontamination in a Patient Room Using Feline Calicivirus and Murine Norovirus as Surrogate Markers for Human Norovirus. <i>Infection Control and Hospital Epidemiology</i> , 2016, 37, 561-566.	1.0	17
44	HIV-1 transmission between MSM and heterosexuals, and increasing proportions of circulating recombinant forms in the Nordic Countries. <i>Virus Evolution</i> , 2016, 2, vew010.	2.2	68
45	Cocirculation of Several Similar But Unique HIV-1 Recombinant Forms in Guinea-Bissau Revealed by Near Full-Length Genomic Sequencing. <i>AIDS Research and Human Retroviruses</i> , 2015, 31, 938-945.	0.5	3
46	High rates of viral suppression in a cohort of HIV-positive adults receiving ART in Ethiopian health centers irrespective of concomitant tuberculosis. <i>Journal of the International AIDS Society</i> , 2014, 17, 19612.	1.2	3
47	High Rates of Virological Suppression in a Cohort of Human Immunodeficiency Virus-Positive Adults Receiving Antiretroviral Therapy in Ethiopian Health Centers Irrespective of Concomitant Tuberculosis. <i>Open Forum Infectious Diseases</i> , 2014, 1, ofu039.	0.4	16
48	Increased survival among HIV-1 and HIV-2 dual-infected individuals compared to HIV-1 single-infected individuals. <i>Aids</i> , 2014, 28, 949-957.	1.0	32
49	The origin and emergence of an HIV-1 epidemic. <i>Aids</i> , 2014, 28, 1031-1040.	1.0	13
50	Consensus HIV-1 subtype A integrase and its raltegravir-resistant variants: Design and characterization of the enzymatic properties. <i>Biochimie</i> , 2014, 102, 92-101.	1.3	8
51	Faster Progression to AIDS and AIDS-Related Death Among Seroincident Individuals Infected With Recombinant HIV-1 A3/CRF02_AG Compared With Sub-subtype A3. <i>Journal of Infectious Diseases</i> , 2014, 209, 721-728.	1.9	33
52	Increased survival among HIV-1 and HIV-2 dual-infected individuals compared to HIV-1 single-infected individuals. <i>Aids</i> , 2014, 28, 949-57.	1.0	9
53	High inpatient HIV-1 evolutionary rate is associated with CCR5-to-CXCR4 coreceptor switch. <i>Infection, Genetics and Evolution</i> , 2013, 19, 369-377.	1.0	18
54	Short-term HIV-1 treatment interruption is associated with dysregulated TLR-stimuli responsiveness. <i>Human Vaccines and Immunotherapeutics</i> , 2013, 9, 2103-2110.	1.4	3

#	ARTICLE	IF	CITATIONS
55	Inhibition of HIV-1 Disease Progression by Contemporaneous HIV-2 Infection. <i>New England Journal of Medicine</i> , 2012, 367, 224-232.	13.9	94
56	HIV-1 Molecular Epidemiology in Guinea-Bissau, West Africa: Origin, Demography and Migrations. <i>PLoS ONE</i> , 2011, 6, e17025.	1.1	55
57	Human immunodeficiency virus type 1 biological variation and coreceptor use: from concept to clinical significance. <i>Journal of Internal Medicine</i> , 2011, 270, 520-531.	2.7	14
58	Differences in molecular evolution between switch (R5 to R5X4/X4-tropic) and non-switch (R5-tropic) Tj ETQq0 0 0 rgBT /Overlock 10 Tf	1.0	39
59	Frequent CXCR4 tropism of HIV-1 subtype A and CRF02_AG during late-stage disease - indication of an evolving epidemic in West Africa. <i>Retrovirology</i> , 2010, 7, 23.	0.9	80
60	Frequent Intrapatient Recombination between Human Immunodeficiency Virus Type 1 R5 and X4 Envelopes: Implications for Coreceptor Switch. <i>Journal of Virology</i> , 2007, 81, 3369-3376.	1.5	48
61	Isolation of human immunodeficiency virus-type 1 (HIV-1) clones with biological and molecular properties of the primary isolate. <i>Virology</i> , 2006, 350, 58-66.	1.1	8
62	Selection of human immunodeficiency virus type 1 R5 variants with augmented replicative capacity and reduced sensitivity to entry inhibitors during severe immunodeficiency. <i>Journal of General Virology</i> , 2005, 86, 2859-2869.	1.3	56
63	Structure and genomic organization of a novel human endogenous retrovirus family: HERV-K (HML-6).. <i>Journal of General Virology</i> , 1997, 78, 1731-1744.	1.3	35